AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 20036404 — intervention group
Group type: EXPERIMENTAL
Intervention: Exercise at simulated altitude of 2000 m
Number of subjects: 7
Study 20036404 — intervention group
Group type: COMPARATOR
Intervention: Exercise at sea level
Number of subjects: 7
Study 18759343 — intervention group
Group type: EXPERIMENTAL
Intervention: Subthalamic nucleus high-frequency stimulation (STN-HFS)
Number of subjects: 10
Study 18759343 — intervention group
Group type: COMPARATOR
Intervention: Control group (healthy individuals)
Number of subjects: 10
Study 16227664 — intervention group
Group type: EXPERIMENTAL
Intervention: RCTs
Number of subjects: 0
Study 16227664 — intervention group
Group type: COMPARATOR
Intervention: Other types of evidence
Number of subjects: 0
Study 12625990 — intervention group
Group type: EXPERIMENTAL
Intervention: Methylphenidate (MPH)
Number of subjects: 31
Study 12625990 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 31
Study 10079411 — intervention group
Group type: EXPERIMENTAL
Intervention: St. John's wort (0.6 mg/mL)
Number of subjects: 0
Study 10079411 — intervention group
Group type: EXPERIMENTAL
Intervention: Saw-palmetto (high concentration)
Number of subjects: 0
Study 10079411 — intervention group
Group type: EXPERIMENTAL
Intervention: Echinacea purpura (high concentration)
Number of subjects: 0
Study 10079411 — intervention group
Group type: EXPERIMENTAL
Intervention: Ginkgo biloba (high concentration)
Number of subjects: 0
Study 10079411 — intervention group
Group type: COMPARATOR
Intervention: Control medium
Number of subjects: 0
Study 7588925 — intervention group
Group type: EXPERIMENTAL
Intervention: Enalapril
Number of subjects: 63
Study 7588925 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 63
Study 2184134 — intervention group
Group type: EXPERIMENTAL
Intervention: Thymopentin (TP-5) at 50 mg s.c. three times per week for one month
Number of subjects: 13
Study 2184134 — intervention group
Group type: COMPARATOR
Intervention: Thymopentin (TP-5)
Number of subjects: 13
Study 7017019 — intervention group
Group type: EXPERIMENTAL
Intervention: Selective antimicrobial modulation (SAM)
Number of subjects: 39
Study 7017019 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 39
Study 30955912 — intervention group
Group type: EXPERIMENTAL
Intervention: HADS-A score ≥ 8
Number of subjects: 88
Study 28295825 — intervention group
Group type: EXPERIMENTAL
Intervention: Manual therapy (n=50), three sessions (once/week) including desensitization manoeuvres of the central nervous system
Number of subjects: 100
Study 28295825 — intervention group
Group type: COMPARATOR
Intervention: Surgery (n=50)
Number of subjects: 100
Study 26141263 — intervention group
Group type: EXPERIMENTAL
Intervention: Nasal filters (Rhinix; Rhinix ApS, Aarhus, Denmark)
Number of subjects: 65
Study 26141263 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 65
Study 23632170 — intervention group
Group type: EXPERIMENTAL
Intervention: Tongue Drive System (TDS)
Number of subjects: 48
Study 23632170 — intervention group
Group type: EXPERIMENTAL
Intervention: tongue-protrusion task (TPT)
Number of subjects: 48
Study 23632170 — intervention group
Group type: EXPERIMENTAL
Intervention: therapeutic tongue exercises (TTE)
Number of subjects: 48
Study 23632170 — intervention group
Group type: COMPARATOR
Intervention: first dorsal interosseous (FDI) (control)
Number of subjects: 48
Study 21321461 — intervention group
Group type: EXPERIMENTAL
Intervention: Atorvastatin 20 mg/d
Number of subjects: 100
Study 21321461 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 100
Study 19762749 — intervention group
Group type: EXPERIMENTAL
Intervention: Advanced cardiac life support
Number of subjects: 1166
Study 19762749 — intervention group
Group type: EXPERIMENTAL
Intervention: Ventricular fibrillation
Number of subjects: 1166
Study 19762749 — intervention group
Group type: EXPERIMENTAL
Intervention: Asystole
Number of subjects: 1166
Study 19762749 — intervention group
Group type: EXPERIMENTAL
Intervention: Logistic regression model
Number of subjects: 1166
Study 17257478 — intervention group
Group type: EXPERIMENTAL
Intervention: Duloxetine
Number of subjects: 23983
Study 15533491 — intervention group
Group type: EXPERIMENTAL
Intervention: Methylprednisolone (n = 34)
Number of subjects: 70
Study 15533491 — intervention group
Group type: COMPARATOR
Intervention: Placebo (n = 36)
Number of subjects: 70
Study 11508581 — intervention group
Group type: EXPERIMENTAL
Intervention: Methotrexate (MTX) in combination with low dose corticosteroids after 12 months of therapy
Number of subjects: 20
Study 11508581 — intervention group
Group type: COMPARATOR
Intervention: Healthy controls
Number of subjects: 20
Study 9635948 — intervention group
Group type: EXPERIMENTAL
Intervention: Cerebral MRI findings
Number of subjects: 80
Study 7826827 — intervention group
Group type: EXPERIMENTAL
Intervention: Bendrofluazide (10 mg)
Number of subjects: 12
Study 7826827 — intervention group
Group type: COMPARATOR
Intervention: Oxazepam (15 mg)
Number of subjects: 12
Study 7826827 — intervention group
Group type: EXPERIMENTAL
Intervention: Bendrofluazide
Number of subjects: 12
Study 7826827 — intervention group
Group type: COMPARATOR
Intervention: Oxazepam
Number of subjects: 12
Study 7826827 — intervention group
Group type: EXPERIMENTAL
Intervention: Bendrofluazide and Oxazepam
Number of subjects: 12
Study 2825820 — intervention group
Group type: EXPERIMENTAL
Intervention: Ethanol
Number of subjects: 0
Study 2825820 — intervention group
Group type: COMPARATOR
Intervention: Ethanol placebo
Number of subjects: 0
Study 29308927 — intervention group
Group type: EXPERIMENTAL
Intervention: High dose CRMRF
Number of subjects: 17
Study 29308927 — intervention group
Group type: EXPERIMENTAL
Intervention: Low dose CRMRF
Number of subjects: 17
Study 29308927 — intervention group
Group type: COMPARATOR
Intervention: Placebo CRMRF
Number of subjects: 17
Study 29308927 — intervention group
Group type: COMPARATOR
Intervention: Control (no intervention)
Number of subjects: 17
Study 29308927 — intervention group
Group type: EXPERIMENTAL
Intervention: High dose PSWT
Number of subjects: 17
Study 26697548 — intervention group
Group type: EXPERIMENTAL
Intervention: Test group (TG) - impingement of periodontal biologic width with transsurgical restorations
Number of subjects: 10
Study 26697548 — intervention group
Group type: COMPARATOR
Intervention: Control group (CG) - supragingival restorations after crown lengthening
Number of subjects: 10
Study 24767220 — intervention group
Group type: EXPERIMENTAL
Intervention: Parkinson's disease patients (H-Y 1-2)
Number of subjects: 55
Study 24767220 — intervention group
Group type: EXPERIMENTAL
Intervention: Parkinson's disease patients (H-Y 3-5)
Number of subjects: 55
Study 24767220 — intervention group
Group type: COMPARATOR
Intervention: Control group (healthy subjects)
Number of subjects: 55
Study 22149129 — intervention group
Group type: EXPERIMENTAL
Intervention: Listening to an interview with fellow cancer survivors (content about negative emotions and effective coping strategies)
Number of subjects: 139
Study 22149129 — intervention group
Group type: COMPARATOR
Intervention: Control condition (not specified)
Number of subjects: 139
Study 20028728 — intervention group
Group type: EXPERIMENTAL
Intervention: NSAIDs/Coxibs (celecoxib, naproxen/ketoprofen)
Number of subjects: 851
Study 20028728 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 851
Study 18578176 — intervention group
Group type: EXPERIMENTAL
Intervention: Renew direct resin composite
Number of subjects: 50
Study 18578176 — intervention group
Group type: EXPERIMENTAL
Intervention: Renew direct resin composite inlay
Number of subjects: 50
Study 18578176 — intervention group
Group type: EXPERIMENTAL
Intervention: Tescera indirect resin composite inlay
Number of subjects: 50
Study 18578176 — intervention group
Group type: COMPARATOR
Intervention: non-restored
Number of subjects: 50
Study 18578176 — intervention group
Group type: EXPERIMENTAL
Intervention: intact
Number of subjects: 50
Study 15706464 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluvoxamine
Number of subjects: 74
Study 15706464 — intervention group
Group type: COMPARATOR
Intervention: Nortriptyline
Number of subjects: 74
Study 12627998 — intervention group
Group type: EXPERIMENTAL
Intervention: Pyridostigmine (45 mg)
Number of subjects: 18
Study 12627998 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 18
Study 10596458 — intervention group
Group type: EXPERIMENTAL
Intervention: Usual dose of insulin (0.1 U/kg)
Number of subjects: 12
Study 10596458 — intervention group
Group type: EXPERIMENTAL
Intervention: Low dose of insulin (0.05 U/kg)
Number of subjects: 12
Study 8763654 — intervention group
Group type: EXPERIMENTAL
Intervention: Surgery and radiotherapy
Number of subjects: 32
Study 8763654 — intervention group
Group type: EXPERIMENTAL
Intervention: Post-operative Karnofski Performance Status
Number of subjects: 32
Study 1913493 — intervention group
Group type: EXPERIMENTAL
Intervention: DDP with DSM (600 mg degradable starch microspheres)
Number of subjects: 8
Study 1913493 — intervention group
Group type: COMPARATOR
Intervention: DDP alone (25 mg/m2)
Number of subjects: 8
Study 7250094 — intervention group
Group type: EXPERIMENTAL
Intervention: 4 miles on alternate days for 1 month
Number of subjects: 15
Study 7250094 — intervention group
Group type: EXPERIMENTAL
Intervention: 8 miles on alternate days for 1 month
Number of subjects: 15
Study 7250094 — intervention group
Group type: COMPARATOR
Intervention: 0 miles on alternate days for 1 month
Number of subjects: 15
Study 31222044 — intervention group
Group type: EXPERIMENTAL
Intervention: Ferric citrate hydrate (FC)
Number of subjects: 93
Study 31222044 — intervention group
Group type: COMPARATOR
Intervention: Control (non-iron-based phosphate binders)
Number of subjects: 93
Study 31313548 — intervention group
Group type: EXPERIMENTAL
Intervention: Triple pill of telmisartan/amlodipine/hydrochlorothiazide
Number of subjects: 512
Study 31313548 — intervention group
Group type: COMPARATOR
Intervention: Dual combination of telmisartan/hydrochlorothiazide
Number of subjects: 512
Study 26794729 — intervention group
Group type: EXPERIMENTAL
Intervention: Docetaxel with Strontium-89 (Sr89)
Number of subjects: 757
Study 26794729 — intervention group
Group type: EXPERIMENTAL
Intervention: Docetaxel with Zoledronic Acid (ZA)
Number of subjects: 757
Study 26794729 — intervention group
Group type: COMPARATOR
Intervention: Docetaxel alone
Number of subjects: 757
Study 26794729 — intervention group
Group type: EXPERIMENTAL
Intervention: Docetaxel with both ZA and Sr89
Number of subjects: 757
Study 24129543 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive‐behavioral therapy (Coping Cat)
Number of subjects: 488
Study 24129543 — intervention group
Group type: EXPERIMENTAL
Intervention: Medication (sertraline)
Number of subjects: 488
Study 24129543 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of cognitive‐behavioral therapy and medication
Number of subjects: 488
Study 24129543 — intervention group
Group type: COMPARATOR
Intervention: Pill placebo
Number of subjects: 488
Study 22282500 — intervention group
Group type: EXPERIMENTAL
Intervention: IL6 donor genotype for rs1800795
Number of subjects: 1298
Study 22282500 — intervention group
Group type: EXPERIMENTAL
Intervention: IL10 associations
Number of subjects: 1298
Study 22282500 — intervention group
Group type: EXPERIMENTAL
Intervention: Other SNPs (IL2, CTLA4, HPSE, MTHFR)
Number of subjects: 1298
Study 20101920 — intervention group
Group type: EXPERIMENTAL
Intervention: Physical Activity (PA) intervention
Number of subjects: 424
Study 20101920 — intervention group
Group type: COMPARATOR
Intervention: Comparison intervention (educational meetings)
Number of subjects: 424
Study 17324657 — intervention group
Group type: EXPERIMENTAL
Intervention: Nutrition intervention (nutrition counseling following the ADA medical nutrition therapy protocol)
Number of subjects: 60
Study 17324657 — intervention group
Group type: EXPERIMENTAL
Intervention: Nutrition intervention
Number of subjects: 60
Study 17324657 — intervention group
Group type: COMPARATOR
Intervention: Standard practice
Number of subjects: 60
Study 15014864 — intervention group
Group type: EXPERIMENTAL
Intervention: Hypromellose and Lacri‐Lube combination (HL)
Number of subjects: 110
Study 15014864 — intervention group
Group type: COMPARATOR
Intervention: Polyethylene covers
Number of subjects: 110
Study 11772822 — intervention group
Group type: EXPERIMENTAL
Intervention: Nicardipine
Number of subjects: 45
Study 11772822 — intervention group
Group type: COMPARATOR
Intervention: Nitroglycerin
Number of subjects: 45
Study 11772822 — intervention group
Group type: COMPARATOR
Intervention: Prostaglandin E(1)
Number of subjects: 45
Study 9659017 — intervention group
Group type: EXPERIMENTAL
Intervention: midazolam 0.08 mg.kg‐1
Number of subjects: 95
Study 9659017 — intervention group
Group type: EXPERIMENTAL
Intervention: morphine 0.15 mg.kg‐1
Number of subjects: 95
Study 9659017 — intervention group
Group type: EXPERIMENTAL
Intervention: clonidine 2 micrograms.kg‐1
Number of subjects: 95
Study 9659017 — intervention group
Group type: COMPARATOR
Intervention: normal saline
Number of subjects: 95
Study 8595681 — intervention group
Group type: EXPERIMENTAL
Intervention: Lidocaine hydrochloride 2% (HCl)
Number of subjects: 45
Study 8595681 — intervention group
Group type: EXPERIMENTAL
Intervention: Alkalinized lidocaine 2% (1 ml NaHCO3 per 10 ml of solution) injected immediately
Number of subjects: 45
Study 8595681 — intervention group
Group type: EXPERIMENTAL
Intervention: Alkalinized lidocaine 2% (1 ml NaHCO3 per 10 ml of solution) injected one hour after preparation
Number of subjects: 45
Study 2668006 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous L-carnitine at a dose of 100 mg kg‐1 b.w. every 12 h for 36 h
Number of subjects: 56
Study 2668006 — intervention group
Group type: COMPARATOR
Intervention: Placebo intravenously
Number of subjects: 56
Study 304442 — intervention group
Group type: EXPERIMENTAL
Intervention: 5 TU Battey test
Number of subjects: 2168
Study 304442 — intervention group
Group type: EXPERIMENTAL
Intervention: 20 TU RT 23 test
Number of subjects: 2168
Study 31187437 — intervention group
Group type: EXPERIMENTAL
Intervention: 300-mg single-dose tafenoquine
Number of subjects: 467
Study 31187437 — intervention group
Group type: COMPARATOR
Intervention: Matched placebo
Number of subjects: 467
Study 28437278 — intervention group
Group type: EXPERIMENTAL
Intervention: Landiolol (12 mg/mL formulation) administered via dose-escalation regimen (10 μg/kg BW/min for 2 hours, 20 μg/kg BW/min for 2 hours, 40 μg/kg BW/min for 20 hours, 6 hours follow-up)
Number of subjects: 12
Study 28437278 — intervention group
Group type: EXPERIMENTAL
Intervention: Landiolol (12 mg/mL formulation)
Number of subjects: 12
Study 25641687 — intervention group
Group type: EXPERIMENTAL
Intervention: Interaction with nurses
Number of subjects: 398
Study 25641687 — intervention group
Group type: EXPERIMENTAL
Intervention: Touch (stress balls)
Number of subjects: 398
Study 25641687 — intervention group
Group type: EXPERIMENTAL
Intervention: Patient selected DVD
Number of subjects: 398
Study 25641687 — intervention group
Group type: EXPERIMENTAL
Intervention: Patient selected music
Number of subjects: 398
Study 25641687 — intervention group
Group type: COMPARATOR
Intervention: Treatment as usual (TAU)
Number of subjects: 398
Study 23072658 — intervention group
Group type: EXPERIMENTAL
Intervention: Qigong exercise program (12 weeks)
Number of subjects: 38
Study 23072658 — intervention group
Group type: COMPARATOR
Intervention: Newspaper reading program (12 weeks)
Number of subjects: 38
Study 21576095 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined infraclavicular block plus distal median, radial, and ulnar nerve blockade
Number of subjects: 61
Study 21576095 — intervention group
Group type: COMPARATOR
Intervention: Infraclavicular block alone
Number of subjects: 61
Study 19695549 — intervention group
Group type: EXPERIMENTAL
Intervention: VCD
Number of subjects: 401
Study 19695549 — intervention group
Group type: COMPARATOR
Intervention: MC
Number of subjects: 401
Study 19695549 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 401
Study 16818564 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin B12 (3 microg/kg per day) and folate (100 microg/kg per day)
Number of subjects: 64
Study 16818564 — intervention group
Group type: COMPARATOR
Intervention: Lower dose of folate (60 microg/kg per day)
Number of subjects: 64
Study 15361820 — intervention group
Group type: EXPERIMENTAL
Intervention: Subclinical hyperthyroidism (HyperT)
Number of subjects: 347
Study 15361820 — intervention group
Group type: EXPERIMENTAL
Intervention: Subclinical hypothyroidism (HypoT)
Number of subjects: 347
Study 15361820 — intervention group
Group type: COMPARATOR
Intervention: Normal subjects (EuT)
Number of subjects: 347
Study 10945496 — intervention group
Group type: EXPERIMENTAL
Intervention: Screening arm (mammographic screening)
Number of subjects: 1029
Study 10945496 — intervention group
Group type: EXPERIMENTAL
Intervention: Operable invasive cases
Number of subjects: 1029
Study 10945496 — intervention group
Group type: EXPERIMENTAL
Intervention: Nottingham Prognostic Index (NPI)
Number of subjects: 1029
Study 10945496 — intervention group
Group type: EXPERIMENTAL
Intervention: Pathological size and histological type
Number of subjects: 1029
Study 10945496 — intervention group
Group type: EXPERIMENTAL
Intervention: Pathology indicators of survival in NPI
Number of subjects: 1029
Study 9390112 — intervention group
Group type: EXPERIMENTAL
Intervention: Montelukast 50 mg
Number of subjects: 27
Study 9390112 — intervention group
Group type: EXPERIMENTAL
Intervention: Montelukast 10 mg
Number of subjects: 27
Study 9390112 — intervention group
Group type: EXPERIMENTAL
Intervention: Montelukast 2 mg
Number of subjects: 27
Study 9390112 — intervention group
Group type: EXPERIMENTAL
Intervention: Montelukast 0.4 mg
Number of subjects: 27
Study 9390112 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 27
Study 8238707 — intervention group
Group type: EXPERIMENTAL
Intervention: Arthroscopic group (fully arthroscopic reconstruction)
Number of subjects: 2
Study 8238707 — intervention group
Group type: COMPARATOR
Intervention: Open group (limited open reconstruction)
Number of subjects: 2
Study 2862946 — intervention group
Group type: EXPERIMENTAL
Intervention: Temazepam (40 mg)
Number of subjects: 0
Study 2862946 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 31285834 — intervention group
Group type: EXPERIMENTAL
Intervention: Mindfulness-based program 'Early Minds' delivered at least three times a week for 8 weeks; educators trained and supported via an app.
Number of subjects: 6
Study 31285834 — intervention group
Group type: EXPERIMENTAL
Intervention: Mindfulness-based program 'Early Minds'
Number of subjects: 6
Study 31285834 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified in detail)
Number of subjects: 6
Study 28651448 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-risk group
Number of subjects: 362
Study 28651448 — intervention group
Group type: EXPERIMENTAL
Intervention: High-risk group
Number of subjects: 362
Study 27127136 — intervention group
Group type: EXPERIMENTAL
Intervention: Acetium lozenge (slow-release L-Cysteine)
Number of subjects: 423
Study 27127136 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 423
Study 25029426 — intervention group
Group type: EXPERIMENTAL
Intervention: Low sodium diet (20 mmol/d)
Number of subjects: 29
Study 25029426 — intervention group
Group type: COMPARATOR
Intervention: Aldosterone infusion (0.7 μg/kg/h for 12.5 h)
Number of subjects: 29
Study 22685046 — intervention group
Group type: EXPERIMENTAL
Intervention: 12-week school-based healthy lifestyle programme (Sport for LIFE)
Number of subjects: 416
Study 22685046 — intervention group
Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 416
Study 18363032 — intervention group
Group type: EXPERIMENTAL
Intervention: Monascus purpureus Went rice (600 mg twice per day for one month, then once daily)
Number of subjects: 72
Study 18363032 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluvastatin (20 mg daily)
Number of subjects: 72
Study 18363032 — intervention group
Group type: COMPARATOR
Intervention: Control group (no antidyslipidemic therapy)
Number of subjects: 72
Study 15601270 — intervention group
Group type: EXPERIMENTAL
Intervention: Dobutamine (n = 12)
Number of subjects: 99
Study 15601270 — intervention group
Group type: COMPARATOR
Intervention: Phenylephrine (n = 12)
Number of subjects: 99
Study 15601270 — intervention group
Group type: COMPARATOR
Intervention: Glyceryl trinitrate (n = 13)
Number of subjects: 99
Study 15601270 — intervention group
Group type: COMPARATOR
Intervention: Intravenous colloid (n = 18)
Number of subjects: 99
Study 12381337 — intervention group
Group type: EXPERIMENTAL
Intervention: Orlistat given as a capsule with the meal
Number of subjects: 12
Study 12381337 — intervention group
Group type: EXPERIMENTAL
Intervention: Orlistat mixed into the test meal before ingestion
Number of subjects: 12
Study 12381337 — intervention group
Group type: COMPARATOR
Intervention: Test meal without Orlistat
Number of subjects: 12
Study 11247198 — intervention group
Group type: EXPERIMENTAL
Intervention: Folic acid containing multivitamin preparation (4 mg of folic acid, calcium, iron, zinc, vitamins A, B1, B2, B6, C, D, and nicotinamide)
Number of subjects: 466
Study 11247198 — intervention group
Group type: COMPARATOR
Intervention: Placebo (calcium and iron only)
Number of subjects: 466
Study 9105061 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluticasone propionate (FP) 250 microg
Number of subjects: 46
Study 9105061 — intervention group
Group type: EXPERIMENTAL
Intervention: Salmeterol xinafoate (SLM) 50 microg
Number of subjects: 46
Study 9105061 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of FP and SLM
Number of subjects: 46
Study 8456421 — intervention group
Group type: EXPERIMENTAL
Intervention: sulotroban (2 mg/min, 4 mg/min, 8 mg/min)
Number of subjects: 21
Study 8456421 — intervention group
Group type: EXPERIMENTAL
Intervention: sulotroban
Number of subjects: 21
Study 8456421 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 21
Study 3104991 — intervention group
Group type: EXPERIMENTAL
Intervention: Enprostil (70 micrograms oral dose)
Number of subjects: 10
Study 3104991 — intervention group
Group type: EXPERIMENTAL
Intervention: Enprostil (10 micrograms/ml) in rats
Number of subjects: 10
Study 31387629 — intervention group
Group type: EXPERIMENTAL
Intervention: Upper-body yoga training
Number of subjects: 84
Study 31387629 — intervention group
Group type: COMPARATOR
Intervention: Abdominal breathing program
Number of subjects: 84
Study 28862373 — intervention group
Group type: EXPERIMENTAL
Intervention: Thalassemic patients
Number of subjects: 0
Study 28862373 — intervention group
Group type: COMPARATOR
Intervention: Healthy individuals (control group)
Number of subjects: 0
Study 26369884 — intervention group
Group type: EXPERIMENTAL
Intervention: Telephone-delivered mutual peer support intervention
Number of subjects: 443
Study 26369884 — intervention group
Group type: COMPARATOR
Intervention: Enhanced usual care (control)
Number of subjects: 443